Navigation Links
Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
Date:6/20/2013

BURLINGTON, Mass., June 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European neurologists identify efficacy improvements in the percentage of seizure-free patients as one of the greatest unmet needs in controlling partial-onset seizures in treatment-refractory epilepsy patients. However, clinical data and the opinions of interviewed thought leaders indicate that none of the five novel agents assessed in the report has clearly demonstrated the potential to fulfill this unmet need, thus leaving considerable opportunity for future therapeutics to bring about meaningful advancements in this arena.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase report entitled Epilepsy: What Type and Magnitude of Clinical Improvements Over Current Mainstays of Treatment Would Make Neurologists and Payers Receptive To a New Therapy? finds that surveyed U.S. neurologists would prescribe the emerging agents profiled—Eisai's Fycompa, UCB's Rikelta and three reformulations of currently available products—to no more than 10 percent of their drug-treated epilepsy patients. Compared with the market-leading, second-generation antiepileptic drug (AED) levetiracetam immediate release (UCB/Otsuka Pharmaceutical's Keppra/E Keppra/Keppra XR, generics), investigational products appear to lack differentiation in efficacy, safety and tolerability, and/or delivery that would be necessary for them to assume a more dominant role in clinical care.

The findings also reveal that 95 percent of surveyed U.S. managed care organization (MCO) pharmacy directors report a willingness to grant preferred formulary status to a drug delivering improvements in seizure-free efficacy, with 45 percent indicating a high willingness. Payers also indicate receptivity to new products that increase the percentage of adult treatment-refractory patients successfully completing a conversion to monotherapy trial and/or more-effectively reduce partial-onset seizure frequency as an adjunctive therapy in pediatric treatment-refractory patients. However, 30-40 percent of surveyed MCO pharmacy directors would require a 75 percent improvement over lamotrigine immediate release (GlaxoSmithKline/Juste's Lamictal, other brands, generics) on these metrics to consider reimbursement, the highest level of improvement assessed in the report.

"While our findings suggest that most payers will require that a drug deliver a strong clinical performance in these arenas to inspire coverage, they indicate they will accept price premiums under either scenario, although tier-dependent cost controls are likely," said Decision Resources Business Insights Analyst John Crowley, Ph.D. "Moreover, conjoint analysis signals neurologists' own price sensitivity for products that cost considerably more than current second- and third- generation AED brands, which generally fall within a range of $10-15/day in the United States."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
2. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
3. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
4. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
5. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
6. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
7. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
8. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
9. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
10. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
11. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Feb. 17, 2017  Ethicon, Inc. today announced ... a privately held medical device company that manufactures ... System, a novel minimally invasive device for the ... Medical will enable Ethicon to offer patients a ... Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... -- Research and Markets has announced the addition of the ... their offering. ... separate comprehensive analytics for the US, Canada , ... , and Rest of World. Annual estimates and forecasts are provided ... provided for these markets. Market data and analytics are derived from primary ...
(Date:2/17/2017)... , Feb. 17, 2017 /PRNewswire/ ... offerings at the  2017 HIMSS Conference & Exhibition (HIMSS17 ... PHIA), a global leader in ... range of population health management, acute ... fully integrated in a highly secure, ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma ... plan partners, announced during the 2017 Annual HIMSS Conference & Exhibition ... for diabetic patients and integrating eye care into mainstream healthcare delivery is powered ...
(Date:2/19/2017)... ... February 19, 2017 , ... The Citadel’s new Swain Department ... being led by Amelia Joseph, Ph.D. Joseph was engaged by the college as a ... department in early 2016. After a nation-wide search, she was selected to head the ...
(Date:2/19/2017)... ... February 19, 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals ... easily reveal any logo with a glitch reveal in just a few clicks of a ... and animation of each preset. Use these presets to add a uniquely animated logo to ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not traditional health ... according to the recent NEJM Catalyst Insights Report on the New Marketplace. ... Insights Council, a qualified group of U.S. executives, clinical leaders, and clinicians at ...
Breaking Medicine News(10 mins):